Abivax’s (ABVX) “Buy” Rating Reaffirmed at BTIG Research

Abivax (NASDAQ:ABVX)‘s stock had its “buy” rating reaffirmed by equities research analysts at BTIG Research in a note issued to investors on Tuesday,Benzinga reports. They currently have a $150.00 price objective on the stock. BTIG Research’s price target indicates a potential upside of 15.66% from the stock’s previous close.

Other research analysts also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research note on Monday, April 20th. Citizens Jmp reaffirmed a “market outperform” rating and set a $131.00 price target on shares of Abivax in a research note on Tuesday, May 26th. Wall Street Zen raised Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Jefferies Financial Group downgraded Abivax to a “hold” rating and set a $90.00 price target for the company. in a research note on Tuesday. Finally, Citigroup reissued an “outperform” rating on shares of Abivax in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Abivax presently has an average rating of “Moderate Buy” and a consensus target price of $131.77.

Abivax Stock Performance

Shares of NASDAQ ABVX opened at $129.69 on Tuesday. The firm has a market capitalization of $10.33 billion, a P/E ratio of -24.89 and a beta of 0.69. Abivax has a one year low of $5.69 and a one year high of $148.83. The company’s fifty day moving average is $118.57 and its two-hundred day moving average is $120.16.

Abivax (NASDAQ:ABVX) last issued its earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $0.40 million. On average, sell-side analysts forecast that Abivax will post -3.27 earnings per share for the current fiscal year.

Institutional Trading of Abivax

Large investors have recently bought and sold shares of the company. GHP Investment Advisors Inc. grew its position in Abivax by 155.6% in the first quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock valued at $26,000 after acquiring an additional 140 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after acquiring an additional 369 shares in the last quarter. Bank of America Corp DE grew its position in Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after acquiring an additional 1,990 shares in the last quarter. Hantz Financial Services Inc. acquired a new stake in Abivax in the third quarter valued at approximately $52,000. Finally, Caitong International Asset Management Co. Ltd grew its position in Abivax by 661.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after acquiring an additional 344 shares in the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.